title: Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.
abstract: The aim of this study was to characterize the pharmacodynamic, pharmacokinetic, and adverse-effect profiles of retigabine (RTG) in combination with carbamazepine (CBZ), lamotrigine (LTG), and valproate (VPA). The isobolographic analysis for parallel and nonparallel dose-response effects was used in the mouse maximal electroshock seizure (MES) model for evaluation of pharmacodynamic interaction. Potential adverse-effect profiles of interactions of RTG with CBZ, LTG, and VPA at the fixed ratio of 1:1 in the MES test were evaluated in the chimney (motor performance), passive avoidance (long-term memory), and grip strength (muscular strength) tests. Free plasma and total brain concentrations of CBZ, LTG, and VPA were determined by immunofluorescence and chromatography to assess pharmacokinetic interaction. In the MES model, RTG administered singly had its dose-response relationship curve (DRRC) parallel to that for VPA and nonparallel to that for CBZ and LTG. With isobolography for parallel DRRCs, the combination of RTG with VPA at fixed ratios of 1:3, 1:1, and 3:1 exerted supraadditive (synergistic) interaction. Isobolography for nonparallel DRRCs revealed that the combinations of RTG with CBZ and LTG at the fixed ratio of 1:1 produced additive interaction. In all combinations, neither motor coordination, long-term memory, nor muscular strength were affected. Only the combination of RTG with VPA at the fixed ratio of 3:1 was complicated by a pharmacokinetic increase in both free plasma and total brain VPA concentrations. All remaining combinations of RTG with VPA, CBZ, and LTG were pharmacodynamic in nature. RTG synergistically interacted with VPA and exerted additive interaction with CBZ and LTG in the mouse MES model.
authors.affiliation: Department of Pathophysiology, Medical University, Lublin, Poland. jarogniew.luszczki@gmail.com
authors.forename: Jarogniew J
authors.initials: JJ
authors.lastname: Luszczki
authors.forename: Jim Z
authors.initials: JZ
authors.lastname: Wu
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Raszewski
authors.forename: Stanislaw J
authors.initials: SJ
authors.lastname: Czuczwar
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D002219:Carbamates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002220:Carbamazepine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004597:Electroshock; D007274:Injections, Intraperitoneal; D000077213:Lamotrigine; D008297:Male; D008568:Memory / Q000187:drug effects; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D053580:Muscle Strength / Q000187:drug effects; D010655:Phenylenediamines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D011597:Psychomotor Performance / Q000187:drug effects; D012640:Seizures / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D014227:Triazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D014635:Valproic Acid / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D000927:Anticonvulsants; D002219:Carbamates; D010655:Phenylenediamines; D014227:Triazines; C101866:ezogabine; D002220:Carbamazepine; D014635:Valproic Acid; D000077213:Lamotrigine
references.citation: Epilepsia. 2003 Aug;44(8):1003-13
references.pmid: 12887431
references.citation: Epilepsia. 2007 Apr;48(4):806-15
references.pmid: 17284299
references.citation: Epilepsia. 2002;43 Suppl 5:86-95
references.pmid: 12121301
references.citation: Drug Metab Dispos. 1999 May;27(5):605-12
references.pmid: 10220490
references.citation: Epilepsia. 2000 Nov;41(11):1364-74
references.pmid: 11077449
references.citation: Mol Pharmacol. 2000 Aug;58(2):253-62
references.pmid: 10908292
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):529-38
references.pmid: 17204358
references.citation: Pharmacol Ther. 2005 Apr;106(1):1-18
references.pmid: 15781119
references.citation: J Clin Pharm Ther. 1993 Jun;18(3):191-7
references.pmid: 8345004
references.citation: Acta Neurol Scand. 1995 Mar;91(3):200-2
references.pmid: 7793236
references.citation: J Clin Pharmacol. 2002 Feb;42(2):175-82
references.pmid: 11831540
references.citation: Neurology. 2007 Apr 10;68(15):1197-204
references.pmid: 17420403
references.citation: Pharmacol Res. 2000 Dec;42(6):553-7
references.pmid: 11058408
references.citation: J Pharmacol Exp Ther. 2004 Sep;310(3):981-6
references.pmid: 15175417
references.citation: Clin Pharmacol Ther. 1980 Oct;28(4):486-92
references.pmid: 6773716
references.citation: Neurosci Lett. 1995 Aug 4;195(2):77-80
references.pmid: 7478272
references.citation: Clin Pharmacol Ther. 2003 Jan;73(1):61-70
references.pmid: 12545144
references.citation: J Pharmacol Exp Ther. 2006 Oct;319(1):1-7
references.pmid: 16670349
references.citation: J Pharmacol Exp Ther. 1949 Jun;96(2):99-113
references.pmid: 18152921
references.citation: Epilepsy Res. 2003 Feb;53(1-2):1-17
references.pmid: 12576163
references.citation: Neurotherapeutics. 2007 Jan;4(1):149-54
references.pmid: 17199031
references.citation: Nat Genet. 1998 Jan;18(1):53-5
references.pmid: 9425900
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1999 Jan;359(1):33-9
references.pmid: 9933148
references.citation: Epilepsy Res. 1999 Jun;35(2):99-107
references.pmid: 10372563
references.citation: J Clin Pharm Ther. 1995 Aug;20(4):215-9
references.pmid: 8557785
references.citation: Seizure. 2002 Sep;11(6):349-51
references.pmid: 12160660
references.citation: Epilepsia. 2007 Mar;48(3):412-34
references.pmid: 17346245
references.citation: Epilepsia. 1979 Jun;20(3):303-11
references.pmid: 376307
references.citation: Arch Neurol. 1983 Dec;40(13):797-802
references.pmid: 6416232
references.citation: Seizure. 2000 Oct;9(7):464-8
references.pmid: 11034869
references.citation: Pharmacol Rev. 1990 Sep;42(3):223-86
references.pmid: 2217531
references.citation: Curr Top Med Chem. 2005;5(1):3-14
references.pmid: 15638774
references.citation: Epilepsy Res. 2004 Jul-Aug;60(2-3):77-159
references.pmid: 15540387
references.citation: Trends Pharmacol Sci. 2008 Apr;29(4):186-91
references.pmid: 18353445
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):330-6
references.pmid: 11284448
references.citation: Epilepsy Res. 1997 Mar;26(3):423-32
references.pmid: 9127723
references.citation: Lancet. 1998 Mar 28;351(9107):958-9
references.pmid: 9734949
references.citation: Acta Neurol Scand Suppl. 1995;162:31-4
references.pmid: 7495187
references.citation: Ther Drug Monit. 1985;7(4):387-90
references.pmid: 3936236
references.citation: Pharmacol Rev. 1989 Jun;41(2):93-141
references.pmid: 2692037
references.citation: Neurosci Lett. 2000 Mar 17;282(1-2):73-6
references.pmid: 10713399
references.citation: Lancet. 1994 Jun 25;343(8913):1650
references.pmid: 7911963
references.citation: CNS Drugs. 2002;16(10):669-94
references.pmid: 12269861
references.citation: Epilepsy Res. 1991 Mar;8(2):79-94
references.pmid: 2065646
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2006 Oct;374(1):51-64
references.pmid: 16972063
references.citation: Epilepsia. 2000 Jan;41(1):28-33
references.pmid: 10643920
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2006 May;373(2):169-81
references.pmid: 16604339
references.citation: Epilepsy Res. 2001 May;44(2-3):155-65
references.pmid: 11325571
references.citation: Eur J Pharmacol. 2003 Mar 19;464(2-3):95-100
references.pmid: 12620500
references.citation: Eur J Pharmacol. 1996 May 15;303(3):163-9
references.pmid: 8813562
references.citation: Nature. 1986 Jun 26-Jul 2;321(6073):864-6
references.pmid: 3724846
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2007 Apr;375(2):105-14
references.pmid: 17333129
references.citation: Epilepsia. 1999 Aug;40(8):1141-6
references.pmid: 10448829
references.citation: J Pharmacol Exp Ther. 1988 Dec;247(3):1128-32
references.pmid: 3144596
references.citation: Pharmacol Rev. 1995 Jun;47(2):331-85
references.pmid: 7568331
references.citation: Eur J Pharmacol. 1999 Dec 15;386(2-3):165-71
references.pmid: 10618466
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):483-92
references.pmid: 18566800
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2004 Apr;369(4):434-46
references.pmid: 14985937
references.citation: Epilepsy Res. 2006 Jun;69(3):183-272
references.pmid: 16835945
references.citation: Neurochem Res. 2005 Dec;30(12):1557-65
references.pmid: 16362775
references.citation: Epilepsia. 2004 May;45(5):424-35
references.pmid: 15101823
references.citation: J Clin Pharmacol. 1997 Dec;37(12):1160-7
references.pmid: 9506012
references.citation: Arzneimittelforschung. 1953 Jun;3(6):285-90
references.pmid: 13081480
references.citation: Epilepsy Res. 2000 Jan;38(1):53-66
references.pmid: 10604606
references.citation: Ther Drug Monit. 1997 Apr;19(2):153-9
references.pmid: 9108642
references.citation: Epilepsy Res. 1988 May-Jun;2(3):145-81
references.pmid: 3058469
references.citation: Neuropsychopharmacology. 2005 May;30(5):958-73
references.pmid: 15525996
references.citation: Epilepsy Res. 2003 Sep;56(1):27-42
references.pmid: 14529951
references.citation: Pharmacol Ther. 2007 Jan;113(1):197-209
references.pmid: 17079019
references.citation: Arzneimittelforschung. 2000 Dec;50(12):1063-70
references.pmid: 11190770
references.citation: Epilepsia. 2003 Apr;44(4):489-99
references.pmid: 12680997
references.citation: Neurobehav Toxicol. 1979 Fall;1(3):233-6
references.pmid: 551317
references.citation: Eur J Pharmacol. 1997 Oct 8;336(2-3):243-9
references.pmid: 9384239
references.citation: Nat Genet. 1998 Jan;18(1):25-9
references.pmid: 9425895
references.citation: Epilepsy Res. 1996 Apr;23(3):211-23
references.pmid: 8739124
references.citation: N Engl J Med. 2000 Feb 3;342(5):314-9
references.pmid: 10660394